Drug Profile
AZD 1656
Alternative Names: AZD1656Latest Information Update: 24 Jan 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; ClinConnect; Conduit Pharmaceuticals
- Class Anti-inflammatories; Antihyperglycaemics; Obesity therapies; Urologics
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Lymphomatous thyroiditis; Preterm labour; Renal failure; Uveitis
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 24 Jan 2024 Phase-II clinical trials in Lymphomatous thyroiditis (unspecified route) before January 2024 (Conduit Pharmaceuticals pipeline, January 2024)
- 24 Jan 2024 Phase-II clinical trials in Preterm labour (unspecified route) before January 2024 (Conduit Pharmaceuticals pipeline, January 2024)
- 24 Jan 2024 Phase-II clinical trials in Renal failure (unspecified route) before January 2024 (Conduit Pharmaceuticals pipeline, January 2024)